-
Mashup Score: 3FDA Approves Novel T-Cell Immunotherapy for Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia - 6 day(s) ago
The U.S. Food and Drug Administration (FDA) approved the CD19-directed genetically modified autologous T-cell immunotherapy obecabtagene autoleucel (Aucatzyl) for adults with relapsed or refractory B-…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 9When Cancer and Cardiovascular Disease Intersect - 6 day(s) ago
The annual Global Cardio-Oncology Summit brings together health-care professionals from diverse disciplines including members of the International Cardio-Oncology Society, the only multidisciplinary p…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet-
When Cancer and Cardiovascular Disease Intersect -@ASCOPost @OncoAlert @oncologynursing https://t.co/yBlms64G8S
-
-
Mashup Score: 9When Cancer and Cardiovascular Disease Intersect - 6 day(s) ago
The annual Global Cardio-Oncology Summit brings together health-care professionals from diverse disciplines including members of the International Cardio-Oncology Society, the only multidisciplinary p…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet-
When Cancer and Cardiovascular Disease Intersect -@ASCOPost @OncoAlert @oncologynursing https://t.co/yBlms64G8S
-
-
Mashup Score: 9When Cancer and Cardiovascular Disease Intersect - 7 day(s) ago
The annual Global Cardio-Oncology Summit brings together health-care professionals from diverse disciplines including members of the International Cardio-Oncology Society, the only multidisciplinary p…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet-
When Cancer and Cardiovascular Disease Intersect -@ASCOPost @OncoAlert @oncologynursing https://t.co/yBlms64G8S
-
-
Mashup Score: 27When Cancer and Cardiovascular Disease Intersect - 8 day(s) ago
The annual Global Cardio-Oncology Summit brings together health-care professionals from diverse disciplines including members of the International Cardio-Oncology Society, the only multidisciplinary p…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet-
When Cancer and Cardiovascular Disease Intersect - The ASCO Post. GCOS meeting highlighted in ASCO post. Let’s continue to work together to improve the cardiovascular health of patients with cancer @ICOSociety https://t.co/FDYC0guAyG
-
-
Mashup Score: 7Nivolumab Plus Ipilimumab in Aggressive Thyroid Carcinoma - 8 day(s) ago
In a single-institution phase II study reported in JAMA Oncology, Sehgal et al found evidence of activity of the combination of nivolumab and ipilimumab in patients with aggressive thyroid carcinoma.
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Nivolumab Plus Ipilimumab in Aggressive Thyroid Carcinoma https://t.co/C12DQuvFhy #thycsm #thyroidcancer #oncology #immunotherapy
-
-
Mashup Score: 7Rachna T. Shroff, MD, MS, FASCO, on Advanced Hepatocellular Carcinoma: Anlotinib Plus Penpulimab vs Sorafenib - 9 day(s) ago
Rachna T. Shroff, MD, MS, FASCO, was the discussant for a phase III trial presented at the ESMO Congress 2024 evaluating the efficacy and safety of anlotinib plus penpulimab vs sorafenib as first-line therapy for advanced hepatocellular carcinoma (Abstract LBA40). Disclaimer: This video transcript has not been proofread or edited and may contain errors. I’ m excited to discuss the results from the phase III APOLLO Study that was presented this year in Barcelona at ESMO 2024. This was a study done
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Rachna T. Shroff, MD, MS, FASCO, on Advanced Hepatocellular Carcinoma: Anlotinib Plus Penpulimab vs Sorafenib https://t.co/kRNHLYrXQ0 #hpbcsm #LiverCancer #ESMO24 @rachnatshroff @UAZCancer
-
-
Mashup Score: 7Nivolumab Plus Ipilimumab in Aggressive Thyroid Carcinoma - 9 day(s) ago
In a single-institution phase II study reported in JAMA Oncology, Sehgal et al found evidence of activity of the combination of nivolumab and ipilimumab in patients with aggressive thyroid carcinoma.
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Nivolumab Plus Ipilimumab in Aggressive Thyroid Carcinoma https://t.co/C12DQuvFhy #thycsm #thyroidcancer #oncology #immunotherapy
-
-
Mashup Score: 0
Josep M. Llovet, MD, PhD, presented the results of the LEAP-012 trial during the Presidential Symposium I at the ESMO Congress 2024 (Abstract LBA3). In this brief summary, Dr. Llovet talks further about how management of hepatocellular carcinoma differs across stages. Disclaimer: This video transcript has not been proofread or edited and may contain errors. Dr Josep Llovet: So hepatocellular carcinoma is a major health problem globally. Is the second cause of cancer-related death, and there are around 1
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Josep M. Llovet, MD, PhD, on Treatment Options in Hepatocellular Carcinoma https://t.co/w1P2ySlQQv #hpbcsm #livercancer #oncology #ESMO24 @IcahnMountSinai
-
-
Mashup Score: 3
The National Comprehensive Cancer Network (NCCN) introduced expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) to account for the advanced understanding of hereditary cancer risk…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
NCCN Guidelines Have Expanded to Meet Growing Understanding of Hereditary Risk https://t.co/8cl6lzVetv #NCCNGuidelines @NCCN #oncology #Genetics
-
.@US_FDA Approves Novel T-Cell Immunotherapy for Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia https://t.co/mNFNXv1Sl9 #leusm #leukemia #hematology #immunotherapy